- Current report filing (8-K)
14 February 2012 - 9:20AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): February 7, 2012
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-35068
|
|
41-2193603
|
(State of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
575 Chesapeake Drive
Redwood City, CA 94063
(Address of principal executive offices and zip
code)
Registrants telephone number, including area code: (650) 216-3500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN
OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
2012 Base Salaries
On February 7, 2012 and February 13, 2012, the Board of Directors (the Board) of AcelRx Pharmaceuticals, Inc. (the
Company) approved the 2012 base salaries (effective retroactively to January 1, 2012) for certain of the Companys named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and
Exchange Commission, the NEOs) in the amounts set forth in the table below.
|
|
|
|
|
Named Executive Officer
|
|
2012 Base Salary
|
|
|
|
Richard A. King, Chief Executive Officer
|
|
$
|
426,006
|
|
|
|
James H. Welch, Chief Financial Officer
|
|
$
|
299,000
|
|
|
|
Pamela P. Palmer, M.D., Ph.D., Chief Medical Officer
|
|
$
|
396,550
|
|
|
|
Lawrence G. Hamel, Chief Development Officer
|
|
$
|
292,800
|
|
|
|
Badri Dasu, Chief Engineering Officer
|
|
$
|
278,000
|
|
Bonus Payments
On February 7, 2012 and February 13, 2012, the Board approved bonus payments for 2011 performance for certain of the NEOs in the amount set forth in the table below, in accordance with the
Companys established 2011 Cash Bonus Plan.
|
|
|
|
|
Named Executive Officer
|
|
2011 Bonus
|
|
|
|
Richard A. King, Chief Executive Officer
|
|
$
|
100,842
|
|
|
|
James H. Welch, Chief Financial Officer
|
|
$
|
67,425
|
|
|
|
Pamela P. Palmer, M.D., Ph.D., Chief Medical Officer
|
|
$
|
89,513
|
|
|
|
Lawrence G. Hamel, Chief Development Officer
|
|
$
|
70,892
|
|
|
|
Badri Dasu, Chief Engineering Officer
|
|
$
|
59,645
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: February 13, 2012
|
|
ACELRX PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
|
/s/ James H. Welch
|
|
|
|
|
James H. Welch
|
|
|
|
|
Chief Financial Officer
|
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Aug 2023 to Aug 2024